CompletedPhase 4

Edaravone-Sodium Ozagrel Comparative Post-Marketing Study on Acute Ischemic Stroke

401 participantsStarted 2004-08

Plain-language summary

This study is randomized, Sodium Ozagrel (Thromboxane A2 Synthase Inhibitor) controlled study on acute ischemic stroke. The primary endpoints were the rate of patients with modified Rankin Scale score of 0-1 at 3 months.

Who can participate

Age range20 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients can be receive drug treatment within 24 hours after stroke onset
✓. Patients with a level of consciousness between 0 (alert) and 3 (unable to recall name and date of birth) according to the Japan Coma Scale
✓. Patients with motor dysfunction of upper and/or lower extremities
✓. Patients aged 20 years or older when giving informed consent

Exclusion criteria

✕. Serum creatinine of \>1.5 mg/dL
✕. Embolic infarction
✕. Intracranial haemorrhage
✕. Large infarction with severe consciousness
✕. Transient ischemic attack (TIA)
✕. A modified Rankin Scale score of ≥2 before stroke onset
✕. Patients were receive drug treatment (argatroban, urokinase, tissue plasminogen activator, heparin, warfarin sodium, aspirin, ticlopidine hydrochloride, cilostazol, edaravone and sodium ozagrel) after stroke onset
✕. Patients were receive surgical treatment or intravascular treatment

What they're measuring

the Rate of Patients With a Modified Rankin Scale Score of 0-1

Timeframe: 3 months

Trial details

NCT IDNCT00200356

SponsorTanabe Pharma Corporation

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Results submitted2012-09-13

View on ClinicalTrials.gov More Cerebral Infarction trials